

FINANCIAL SUPERVISION AUTHORITY

Current report No. 10/2019

Date prepared: 2019-04-24

Abbreviated name of issuer: MABION S.A.

Subject: Submission of answers as part of the registration procedure for MabionCD20 at the European Medicines Agency.

Contents of the report

With reference to Current Reports no. 36/2018 of 1 June 2018 and no. 46/2019 of 21 June 2019 on the submission and acceptance for assessment of the market authorisation application for the medicine with the working name MabionCD20 by the European Medicines Agency _"EMA"_, the Management Board of Mabion S.A. _"Company"_ hereby informs that on April 24, 2019 it submitted answers to the EMA questions received as part of the Day 120 stage of the registration procedure for the MabionCD20 drug at the EMA. The submission of answers to the EMA questions _Day 121_ makes it possible for the Agency to further the application assessment.

The Company informs that submitting the answers referred to in the above mentioned report does not guarantee that the product will be approved by the European Medicines Agency.